You are here

  • Home
  • Archive
  • Volume 27, Issue 6
  • Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer

Article info

Article menu
Download PDFPDF
Cervical Cancer
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer

Authors

  1. Address correspondence and reprint requests to Aijing Shang, MD, PhD, MORSE-HTA Group, Global Pricing and Market Access, Pharmaceuticals Division, F. Hoffmann-La Roche Ltd, Room 13.S643, Building 001, 4070 Basel, Switzerland. E-mail: aijing.shang{at}roche.com.

Citation

Rosen VM, Guerra I, McCormack M, et al
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
International Journal of Gynecologic Cancer 2017;27:1237-1246.

Publication history

  • Received August 11, 2016
  • Accepted December 8, 2016
  • First published July 1, 2017.
Online issue publication 
February 27, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.